Cotinine is not considered addictive in humans based on current evidence. It is the primary metabolite of nicotine, meaning your body produces it naturally when breaking down nicotine, and it lingers in the bloodstream far longer than nicotine itself. While animal studies show cotinine has mild reinforcing properties, human trials have found no measurable subjective effects, no euphoria, and no withdrawal symptoms, even at doses ten times higher than what a smoker’s body normally produces.
How Cotinine Differs From Nicotine
When you consume nicotine through smoking, vaping, or nicotine replacement products, your liver converts roughly 70–80% of it into cotinine. Nicotine itself has a plasma half-life of about two hours, meaning it clears from your blood relatively quickly. Cotinine sticks around much longer, with a half-life of 16 to 18 hours. That persistence is why cotinine is the standard biomarker used in drug tests, insurance screenings, and research studies to determine whether someone has been exposed to tobacco or nicotine products.
Despite its longer presence in the body, cotinine is dramatically weaker than nicotine at activating the same brain receptors. Depending on the receptor type and the study, cotinine is anywhere from 200 to over 10,000 times less potent than nicotine at binding to nicotinic receptors in the brain. At the high-affinity receptors most closely linked to nicotine addiction, cotinine is essentially inactive at the concentrations found in a smoker’s bloodstream.
What Animal Studies Show
Rats will self-administer cotinine when given the opportunity through an intravenous line, pressing a lever to receive doses. In these experiments, rats pressed the active lever more than the inactive one and gradually increased their effort to obtain cotinine when researchers made it harder to get. This pattern of behavior suggests cotinine has some reinforcing properties, meaning it produces enough of a reward signal for animals to seek it out.
However, the reinforcing effect is considerably weaker than nicotine’s. Breakpoints, which measure how hard an animal is willing to work for a dose, ranged from 7 to 10 per session for cotinine compared to higher values for nicotine. Cotinine also raises dopamine levels in the brain’s reward center, but this effect is described as “much less robust” than nicotine’s. One study found intravenous cotinine increased dopamine by roughly 30–40% above baseline, though the results were so variable they didn’t reach statistical significance. By comparison, nicotine produces a sharp, reliable dopamine spike that reinforces repeated use.
Cotinine can trigger dopamine release from brain tissue at concentrations 200 to 750 times higher than what nicotine requires to produce the same effect. At the concentrations that naturally occur in your blood after smoking, cotinine is unlikely to produce meaningful reward signaling on its own.
What Happens in Humans
The most telling evidence comes from a clinical trial that gave cotinine directly to human volunteers at doses producing blood levels up to ten times what a heavy smoker would have. Researchers measured physiological responses, cognitive performance, and subjective feelings like mood changes or any sense of a “buzz.” The results: no significant effects across any measure compared to placebo. Participants did not report feeling anything different, did not show signs of stimulation or relaxation, and showed no withdrawal effects when cotinine was stopped.
This is a striking contrast to nicotine, which produces noticeable alertness, mood changes, and appetite suppression even at moderate doses, and which causes well-documented withdrawal symptoms including irritability, difficulty concentrating, and cravings within hours of the last dose.
Why the Distinction Matters
Cotinine has attracted interest as a potential therapeutic compound precisely because it appears to interact with the brain without producing addiction. Researchers have studied it for possible cognitive benefits, particularly in conditions involving memory impairment. Its long half-life and lack of subjective effects make it a candidate that could theoretically offer some of nicotine’s cognitive properties without the dependence risk.
For people wondering whether cotinine showing up on a drug test means they’re exposed to an addictive substance: the cotinine itself is not what creates nicotine dependence. It is simply evidence that nicotine entered the body at some point in the previous few days. The CDC defines secondhand smoke exposure as serum cotinine levels between 0.05 and 10 ng/mL, levels far too low to produce any psychoactive effect even if cotinine were capable of one.
The Bottom Line on Addiction Risk
Cotinine sits in an unusual category. It activates some of the same biological pathways as nicotine, but so weakly that the effect doesn’t translate into anything a person can feel or become dependent on. Animal research confirms it has mild reinforcing properties at artificially high doses delivered directly into the bloodstream, but human data shows no subjective effects, no craving, and no withdrawal. Cotinine is not classified as a controlled substance, and no regulatory body treats it as an addictive compound. If you encounter cotinine in a lab result or product label, it is not itself a substance with meaningful addiction potential.